This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Does VistaGen Therapeutics, Inc. (VTGN) Have the Potential to Rally 160% as Wall Street Analysts Expect?
by Zacks Equity Research
The mean of analysts' price targets for VistaGen Therapeutics, Inc. (VTGN) points to a 160% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?
by Zacks Equity Research
Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
How Vistagen (VTGN) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Vistagen (VTGN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Biotech Stock Roundup: SAGE, GRTX Plunge on Setback, REGN to Buy DBTX & More News
by Zacks Equity Research
Regulatory updates from SAGE and Galera (GRTX) are in focus in the biotech sector.
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 16.67% and 41.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
BioCryst (BCRX) Down as it Discontinues Developing PNH Drug
by Zacks Equity Research
BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.
Cytokinetics (CYTK) Up Despite Unfavorable FDA Committee Voting
by Zacks Equity Research
Cytokinetics (CYTK) gets an unfavorable recommendation from CRDAC on omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction.
What Makes VistaGen Therapeutics, Inc. (VTGN) a New Buy Stock
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 0% and 388.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Adma Biologics (ADMA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of 22.22% and 8.77%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Beam Therapeutics Inc. (BEAM) delivered earnings and revenue surprises of 5.56% and 26.87%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
VistaGen Therapeutics, Inc. (VTGN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -33.33% and 88.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Nurix Therapeutics, Inc. (NRIX) Soars 14.5%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Nurix Therapeutics, Inc. (NRIX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Bristol Myers' (BMY) Opdivo Data Positive for Neoadjuvant NSCLC
by Zacks Equity Research
Bristol Myers (BMY) posts favorable data from a late-stage study that shows neoadjuvant Opdivo with chemotherapy to significantly better the event-free survival rate in patients with resectable NSCLC.
Gilead (GILD) Magrolimab Studies' Partial Clinical Hold Removed
by Zacks Equity Research
Gilead (GILD) studies evaluating its investigational agent magrolimab in combination with Vidaza are no longer under FDAs partial clinical hold.
Novartis (NVS) Anti-PD-1 Drug Validated by EMA for Lung Cancer
by Zacks Equity Research
Novartis (NVS) application seeking approval of tislelizumab in multiple non-small cell lung cancer and esophageal squamous cell carcinoma indications gets EMA's validation.
Bristol Myers (BMY) Gets EC Nod for Opdivo's Label Expansion
by Zacks Equity Research
Bristol Myers (BMY) receives EC approval for label expansion of Opdivo for ESCC and urothelial carcinoma.
VistaGen Therapeutics, Inc. (VTGN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 37.50% and 8.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: VistaGen Therapeutics, Inc. (VTGN) Q3 Earnings Expected to Decline
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -40.00% and 9.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will VistaGen Therapeutics, Inc. (VTGN) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Sage, Biogen Plan to File Zuranolone NDA for MDD in 2022
by Zacks Equity Research
Sage (SAGE) and partner Biogen are looking to get approval for zuranolone as an oral treatment for major depressive disorder. They will start rolling submission of an NDA in early 2022 for the candidate.
VistaGen Therapeutics, Inc. (VTGN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 20.00% and -4.58%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Sage Stock Declines on Late-Stage Depression Study Data
by Zacks Equity Research
Sage is developing zuranolone as a potential treatment for major depression disorder in late-stage studies.
New Strong Sell Stocks for March 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today